IPO prospectus, SteadyMed is a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of market-leading products in certain orphan and other well-defined, high-margin specialty markets. Orphan markets involve rare diseases or conditions and, in the United States, orphan drug designation may be available for a drug intended to treat a rare disease that affects fewer than 200,000 individuals in the United States. Its primary focus is to obtain approval for the sale of Trevyent® for the treatment of pulmonary arterial hypertension, or PAH. Its is also developing two product candidates for the treatment of post-surgical and acute pain in the home setting. SteadyMed’s family of PatchPumps can be customized to deliver liquid drugs, including biologics, with a wide range of volumes and viscosities, in a consistent and controllable manner. PatchPump is the most size efficient and scalable delivery product for injectable drugs.
SteadyMed aspires to redefine the parenteral therapeutics experience for patients dependent upon large doses of intravenous and subcutaneous medications, with the goal of extending the limits of parenteral therapeutics to restore freedom, joy and dignity to patients’ lives.